Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Rising Leverage
AIAI Summary
DYN is now a catalyst-driven, increasingly binary biotech: its strong cash runway supports execution through 2028, but value depends on January 2027 FDA approval of z-rostudirsen and functional DM1 data—not biomarkers alone—while failure in either could renew dilution and undermine the FORCE platform thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Rising Leverage
DYN has strong liquidity but worsening leverage, persistent heavy losses, negative cash flow, and elevated valuation make it a high-risk investment dependent on external financing.
Price Behavior
Key Price Behavior Insights:
- •Steep downtrend
- •Support at risk
- •Extreme oversold
DYN is in a steep bearish downtrend over the last month, with $17.10–$17.30 support at risk despite extreme oversold conditions that could trigger a short-lived rebound.
Price fell roughly 34% over the last month, accelerating after
Sentiment & News
Key News Insights:
- •DM1 trial concerns
- •Pipeline data ahead
- •Strong call buying
Novartis's DM1 trial failure heightened skepticism around Dyne's clinical path, pressuring shares despite ongoing pipeline progress and unusually bullish call activity.
Near-term sentiment is likely volatile as investors weigh sector-wide efficacy doubts against Dyne's upcoming clinical updates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings